Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-08T05:21:23.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol

Published online by Cambridge University Press:  16 April 2020

J. Peuskens ,
B. Gillain ,
D. De Graeve ,
B. Van Vleymen  and
A. Albert
J. Peuskens*
Affiliation:
Universitair Psychiatrisch Centrum Katholieke Universiteit Leuven, Campus St. Jozef Kortenberg, Leuvensesteenweg 517, 3070Kortenberg, Belgium
B. Gillain
Affiliation:
Université Catholique Louvain, Avenue Hippocrate 10, 1200Bruxelles, Belgium
D. De Graeve
Affiliation:
University of Antwerp, Faculty of Applied Economics, Department of Economics, University of Antwerp, Prinsstraat 13, 2000Antwerpen, Belgium
B. Van Vleymen
Affiliation:
Eli Lilly, Medical Department, Stoofstraat 52, 1000Brussels, Belgium
A. Albert
Affiliation:
University of Liège, Department of Biostatistics, CHU, Sart Tilman, 4000Liège, Belgium
*
*Corresponding author. Tel.: +32 2 758 0503; fax: +32 2 758 0511. E-mail addresses: [email protected] (J. Peuskens), [email protected] (B. Gillain), [email protected] (D. De Graeve), [email protected] (B. Van Vleymen), [email protected] (A. Albert).
Get access

Abstract

Objectives

This Schizophrenia Outcome Survey compared medical costs, psychopathology and adverse events in outpatients for 2 years following hospitalisation for an acute schizophrenic episode.

Methods

Adults stabilised with haloperidol, olanzapine or risperidone entered this observational study ≤1 month after discharge and were assessed at baseline, 3, 6, 12, 18 and 24 months using Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), Global Assessment of Functioning and adverse events reporting.

Results

Among 323 patients (haloperidol 32, olanzapine 149, risperidone 142), baseline characteristics were similar in the olanzapine and risperidone groups, except for more first episodes in the risperidone group (p = 0.01). Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly). Sixty-eight percent of patients completed a 2-year follow-up. In all groups, CGI and GAF improved during the first 3 months (both p < 0.0001) while BPRS deteriorated in the first year (all within group changes p < 0.05, between group changes NS) before it stabilised. There were no significant differences in hospitalisations and no change in social profile. At the last visit, 66% of haloperidol (p < 0.01), 35% of olanzapine (NS) and 39% (NS) of risperidone patients had ≥1 EPS; 69% (p < 0.013), 40 and 44%, respectively, had ≥1 sexual problem (NS). Mean weight gain was 0.4 (NS), 2.6 (p < 0.05) and 2.6 kg (p < 0.05), respectively.

Conclusions

In this naturalistic study, treatment allocation might have introduced a bias in the interpretation of efficiency results, but olanzapine and risperidone caused less EPS than haloperidol during 2 years of outpatient follow-up.

Keywords

OlanzapineRisperidoneHaloperidolSchizophreniaTreatment continuationMaintenance treatment
Type
Original article
Information
European Psychiatry , Volume 24 , Issue 3 , April 2009 , pp. 154 - 163
Copyright
Copyright © Elsevier Masson SAS 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Tel.: +32 2 764 2121; fax: +32 10 688 322.

2

Tel.: +32 3 220 4170; fax: +32 3 220 4585.

3

Tel.: +32 2 548 8469; fax: +32 2 548 8416.

4

Tel.: +32 4 366 2590; fax: +32 4 366 2596.

References

Bobes, J., Garc A-Portilla, M.P., Rejas, J., Hern Ndez, G., Garcia-Garcia, M., Rico-Villademoros, F.et al.Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125–147CrossRefGoogle ScholarPubMed
Csernansky, J.G., Mahmoud, R., Brenner, R.A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22CrossRefGoogle ScholarPubMed
Davis, J.M., Chen, N.Old versus new: weighing the evidence between the first-and second generation antipsychotics. Eur Psychiatry 2005;20(1):7–14CrossRefGoogle ScholarPubMed
Davis, J.M., Chen, N., Glick, I.D.A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553–564CrossRefGoogle ScholarPubMed
De Graeve, D., Peuskens, J., Gillain, B., Albert, A., Debackere, N., Van Vleymen, B.A description of direct medical costs in patients with schizophrenia and initiated on haloperidol, olanzapine or risperidone. Acta Psychiatrica Belgica 2007;107/4:31–39Google Scholar
De Hert, M., Thys, E., Boydens, J., Gilis, P., Kesteloot, K., Verhaegen, L.et al.Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519–527CrossRefGoogle ScholarPubMed
Dossenbach, M., Erol, A., el Mahfoud Kessaci, M., Shaheen, M.O., Sunbol, M.M., Boland, J.et al.Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004;65:312–321CrossRefGoogle ScholarPubMed
Guy, W.Clinical global impressionECDEU Assessment Manual for Psychopharmacology (revised) Rockville, MDNational Institute of Mental Health 1976 217–221Google Scholar
Haro, J.M., Novick, D., Suarez, D., Alonso, J., Lépine, J.P., Ratcliffe, M.SOHO study group. Remission and relapse in the outpatient care of schizophrenia: 3-year result from SOHO study. J Clin Psychopharmacol 2006;26(6):571–578CrossRefGoogle Scholar
Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.E.Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115–1121CrossRefGoogle ScholarPubMed
http://statbel.fgov.beGoogle Scholar
Jones, S.H., Thornicroft, G., Coffey, M., Dunn, G.A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654–659CrossRefGoogle Scholar
Kay, S., Ople, L., Fiszbein, A.Positive and Negative Syndrome Scale (PANSS) Manual North Tonawada, New YorkMulti-Health Systems 1986Google Scholar
Knegtering, H., Boks, M., Blijd, C., Castelein, S.van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006;32:315–326CrossRefGoogle Scholar
Leucht, S., Barnes, T.R., Kissling, W., Engel, R.R., Correll, C., Kane, J.M.Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160(7):1209–1222CrossRefGoogle ScholarPubMed
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O.et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223CrossRefGoogle ScholarPubMed
Mazzaglia, G., Mantovani, L.G., Sturkenboom, M.C., Filippi, A., Trifiro, G., Cricelli, C.et al.Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005;23:2093–2100CrossRefGoogle ScholarPubMed
Peuskens, J., Moore, N., Azorin, J.M., Toumi, M., Cochran, J.The European Sertindole Safety and exposure survey: a follow-up of 8600 patients. Pharmacoepidemiol Drug Saf 2007;16:1–8CrossRefGoogle ScholarPubMed
Stroup, T.S., McEvoy, J.P., Swartz, M.S., Byerly, M.J., Glick, I.D., Canive, J.M.et al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15–31CrossRefGoogle ScholarPubMed
Tiihonen, J., Wahlbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J.P.A., Volavka, J.et al.Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224–229CrossRefGoogle Scholar
Tollefson, G.D., Beasley, C.M. Jr.Tran, P.V., Street, J.S., Krueger, J.A., Tamura, R.N.et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–465Google ScholarPubMed
Tran, P.V., Dellva, M.A., Tollefson, G., Wentley, A.L.Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499–505CrossRefGoogle ScholarPubMed
Williams, R., Kopala, L., Malla, A., Smith, G., Love, L., Balshaw, R.Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand 2006;113(Suppl 430):12–21CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.